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Results: A total of 76 patients (61±15 years, 35 male/41 female) had a mean BNP (pg/
ml) of 2766± 1398 (SD) of whom 50 (66%) had LVEF >40 and only 17 (22%) had VOL.
All patients had a recent history of cancer- 34 (45%) had a hematological malignancy
and 42 (55%) had a solid tumor. 43 patients (57%) had evidence of sepsis. Of these 43
patients, 40 did not have VOL and 35 had LVEF>40. The BNP values, although all ele-
vated, were higher in VOL (3463±1439, n=17) versus NO VOL (2565±1332, n=59)
p<0.05. Similarly, BNP values were higher if LVEF<40 (3273±1474, n=26) versus
LVEF>40 (2502±1294, n=50), p<0.05 by ANOVA.
Conclusion: Markedly elevated BNP values obtained on cancer patients admitted with
multiple co-morbidities may not reliably indicate VOL or reflect LV dysfunction. In patients
with cancer and infectious complications, therapeutic decisions may need to be guided
more by clinical evidence as opposed to laboratory evidence of HF or VOL. It is possible
that other factors, such as IL-6 or other cytokines, may stimulate BNP release in the
absence of significant VOL or perhaps interfere with the standard assay giving errone-
ously high values.
1049-117 B-Type Natriuretic Peptide Is a Biochemical Predictor of 
Myocardial Contractile Reserve During Dobutamine 
Stress Echocardiogram
Ann Tong, Daniel Lenihan, Vivjay Divakaran, Jessica M. Tristan, Mona Nemer, Joseph 
Swafford, Gregory Geisler, Mary Vooletich, Beverly Handy, Jean-Bernard Durand, 
University of Texas, M.D. Anderson Cancer Center, Houston, TX
Dobutamine Stress Echocardiography (DSE) is used to assess myocardial contractile
reserve (CR) in ischemic and dilated cardiomyopathy (CMP). A higher CR is associated
with improved prognosis and LVEF with optimal therapy. No data is available in patients
with chemotherapy-induced CMP. Technical limitations due to imaging may reduce the
diagnostic ability of DSE. Brain Natriuretic Peptide (BNP), a neurohormone secreted
from the ventricle in response to volume overload, may provide additional predictive
power to DSE.
We hypothesized that BNP can be used as a biochemical marker for CR and may
improve diagnostic capability of DSE. BNP levels were obtained at baseline and peak
infusion during DSE in 42 patients (23 men, 19 women) with LVEF < 45%. Baseline
demographics: mean age 61±14 yrs, prior chemotherapy 67%, ischemic heart disease
34%, hypertension 36%, diabetes 12%, and NYHA class 2.3±0.9. Patients were catego-
rized based on response of BNP during DSE: Group 1 (n=22, BNP falls) and Group 2
(n=20, BNP rises). See Table 1. With linear regression analysis, there was a significant
inverse correlation between changes in BNP and LVEF pre and post DSE (r=0.6,
p<0.001). 
BNP can identify CR in conjunction with DSE and may be helpful in technically difficult 
studies. A decrease in BNP after DSE is strongly correlated with the presence of CR as 
shown by an increase in LVEF. In chemotherapy-induced CMP, a condition generally con-
sidered irreversible, BNP in conjunction with DSE may predict improvement of cardiac 
function.
1049-118 N-Terminal Pro-Brain Natriuretic Peptide and Urinary 
Albumin Excretion Is Independent Predictors of All 
Cause Mortality in the General Population
Caroline Kistorp, Ilan Raymond, Frants Pedersen, Jens Faber, Per Hildebrandt, 
Frederiksberg University Hospital, Frederiksberg, Denmark
Background: N-terminal proBNP (NT-proBNP) and urinary albumin excretion is known
important risk factors for mortality in patients with chronic heart failure (CHF) and diabe-
tes mellitus, respectively. It is unclear whether these unconventional risk factors are inde-
pendent predictors of all cause mortality in the general population.
Methods: A total of 658 subjects (age 51-91 years), were consecutively recruited from 4
general practitioners in the Frederiksberg municipality. All subjects underwent echocar-
diography, measuring left ventricular ejection fraction (LVEF), and plasma NT-proBNP
and urinary albumin/creatinine ratio (A/C ratio) were measured at baseline. Mean follow-
up time was 48 months. Using multivariate Cox proportional hazard models, the prognos-
tic value of the upper quartile of plasma NT-proBNP and urinary A/C ratio was evaluated
in two models: Model 1 (total population). Model 2 (after exclusion of patients with known
heart failure or LVEF <=50 %, as well as, diabetes by history or HbA1c >= 6.1 %).
Results: During follow-up there were 55 (8.4 %) deaths from any cause in the total pop-
ulation (n = 658). Plasma levels of NT-proBNP and urinary A/C ratio in the upper quartile,
was associated with increased risk for total mortality. For NT-proBNP, hazard ratio (HR)
was 3.6 (95% CI: 1.6-6.7, p < 0.0001); for urinary A/C ratio, HR was 2.6 (95% CI: 1.4-4.9,
p=0.002). In model 2 (n = 495) mortality rates were 5.3 %. For NT-proBNP, HR was 2.8
(95% CI: 1.3-6.2, p=0.009); for urinary A/C ratio, HR was 5.1 (95% CI: 1.8-13.9,
p=0.0019), after adjustment for age, gender, LVEF and established risk factors in both
models. Median urinary A/C ratio (mg/g) and plasma NT-proBNP (pmol/l) levels in sub-
jects who died was 20 mg/g (4-274), and 94.0 pmol/l (18.3-1633.2), compared with 6 mg/
g (3-66) and 30.1 pmol/l (5.2-202.6) in survivors, p < 0.0001 for both.
Conclusion: Plasma NT-proBNP and urinary albumin are independent risk factors for
total mortality in the general population. Even when excluding patients with conditions
associated with increased plasma NT-proBNP and urinary albumin excretion, both
unconventional risk factors remained strong prognostic predictors.
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1050-120 Echocardiographic and Angiographic Correlations in 
Cardiogenic Shock
M. Joshua Berkowitz, Shannon Harkness, Judith Hochman, Michael Picard, Timothy 
Sanborn, Norma Keller, James Slater, New York University Hospital, New York, NY
Objectives: We investigated the correlation between echocardiographic and angio-
graphic core lab data in patients with cardiogenic shock (CS) complicating AMI.
Background: In patients with CS complicating AMI, both echocardiographic and angio-
graphic findings are used to aid diagnosis, determine prognosis, and guide management.
The purpose of this study of the SHOCK trial is to identify relationships between the
angiographic and echocardiographic features of patients with CS. Such an analysis may
provide insights into the etiology and treatment of CS.
Methods/Results: Of 302 randomized patients, a pre-revascularization echocardiogram
and angiogram was available in 119 patients. The correlations between almost all echo
and angiographic parameters collected within 4 hours and greater than 4 hours of each
other were similar. Although the median ejection fraction (EF) derived by echo and LV
angiogram was identical, 29.5%, this significant positive correlation was weak (R2=.209,
p=.019) as was the significant negative correlation between EF and angiographic jeop-
ardy scores (R2=.145, p=.001). Although the presence of left main obstruction (>50%
stenosis) was associated with lower LVEF (26% vs.31%, p= .031) there was only a trend
for decreasing EF with number of diseased vessels. Patients with a higher number of dis-
eased vessels had worse MR by echo (p=.005). There was a significant but weak associ-
ation between LV gram MR grade and echo MR severity (R2=.162, p=.015), but there
was no association between culprit vessel and degree of MR. Patients with TIMI grade 0/
1 were more likely to have impaired LV function (p=.029). Collateral flow to the culprit
vessel was not associated with improved EF. There was a trend towards an increased
incidence of LV thrombus in LAD culprit vessels (p=.060).
Conclusions: Higher angiographic jeopardy scores and low TIMI flow scores are associ-
ated with worse LV function but collateral flow to the culprit vessel is not associated with
improved EF by echo. Worse CAD is associated with more severe MR. Both echo and
angiography are valuable and result in similar estimated EF's in a large cohort however
there is wide variation between the techniques in individual patients.
1050-121 Echocardiographic, Electrophysiological, Histological, 
and Serological Recovery During Left Ventricular Assist 
Device Support
Steve Xydas, Jason Cohen, Yoshifumi Naka, Donna M. Mancini, Marco DiTullio, Amanda 
D. Arnold, Chuck Ng, Mehmet C. Oz, Simon Maybaum, Columbia University College of 
Physicians and Surgeons, New York, NY
Background: Mechanical unloading during left ventricular assist device (LVAD) support
may lead to cardiac recovery, however, clinical markers of recovery have yet to be identi-
fied. We sought to define the echocardiographic (echo), EKG, serological and histologi-
cal changes during device support.
Methods: LVAD patients underwent monthly evaluation, including echo, EKG and serum
BNP measurement. Paired myocardial tissue samples from implant and explant were
analyzed.
Results: 32 LVAD patients were prospectively followed. Duration of heart failure was
47.3 ± 99.1 months and duration of support was 103.2 ± 85 days. Left ventricular ejection
fraction (LVEF) and end-diastolic diameter significantly improved at 30 days as compared
to pre-LVAD, with no further improvement with longer periods of support. At 30 and 60
days, QTc and QRS were significantly decreased from pre-LVAD. There was a marked
reduction in BNP, myocyte size, and collagen deposition during LVAD support. In screen-
ing for markers of recovery, the decrease in QTc correlated with LVEF at 30 days (R = -
0.993, p < .01). Interestingly, changes in QRS correlated with the drop in myocardial col-
lagen deposition (R = -0.976, p < .01). No study patients had sufficient recovery for
device explantation.
Conclusions: We demonstrate echo, EKG, histologic, and serological improvement dur-
ing LVAD support. Recovery is evident at 30 days and is sustained through 90 days of
support. Further prospective data collection may yield important markers of recovery.
Table 1
Change in 
BNP(pg/ml)
Pre-DSE 
LVEF(%)
Post- 
DSE  
LVEF (%)
Change in 
LVEF(%)*
Group 1 (fall in BNP) -110±90 35±9 49±11 14±5
Group 2 (rise in BNP) 68±84 33±9 38±12 4±8
all data is mean ± SD
* change in LVEF inversely correlates with change in BNP, <0.001
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1050-122 Outcomes With Patients of Variable Body Surface Area 
and Long-Term Use of the DeBakey Ventricular Assist 
Device®
Edward Teitel, Marco Turina, Roland Hetzer, George Noon, Hans Scheld, Ettore Vitali, 
Ernst Wolner, MicroMed Technology, Inc., Houston, TX
Background: Ventricular assist devices (VADs) are now accepted treatment for end-
stage heart failure as bridge-to-transplant.Based on the REMATCH trial, the HeartMate®
device has been approved by the FDA for destination therapy. New generation devices
offer the hope for smaller, more reliable support as we move to new indications such as
destination therapy. The miniaturized, continuous flow DeBakey VAD® has been the
most widely used new generation VAD, with over 200 implants worldwide.
Methods: The clinical report forms for completed patients and notes from weekly patient
monitoring conferences for ongoing patients were examined on 157 patients at 6 sites in
Europe.
Results: At pump speeds ranging from 8-11,500rpm (mean 9600 rpm) regardless of
BSA, pump output (mean 4.5 l/min) increased with increasing BSA (slope 1.77)(p <
0.001). Mean arterial pressures and end organ function, as indicated by BUN, creatinine,
and total bilirubin remained in the normal range regardless of BSA. Twenty-five patients
were supported > 6 months and 6 patients were supported > 1 year. Of the 25 who were
supported > 6 months, 16 (64%) went on to transplant, 2 (8%) are still on support, and 7
(28%) died. Five of the patients on support over a year were transplanted and one died.
Forty-three were discharged for a total of 3821 discharge days, or 10.46 patient-years.
(2-342 days). (Some patients were not eligible for discharge because of institutional or
regulatory constraints.) Twenty-five patients had 50 hospital readmissions. These read-
mitted patients spent 2974 days out of the hospital (8.15 patient-years). 70% of those dis-
charged, were either transplanted or remain well on long-term support at home.
Conclusion: The DeBakey VAD adequately supports patients from 1.2-2.3 m2 BSA.
DeBakey VAD patients on long-term support can be successfully managed at home with
excellent outcomes.
1050-123 Neurological Events With a Totally Implantable Left 
Ventricular Assist System: The European LionHeart 
Clinical Utility Baseline Study (CUBS)
John P. Boehmer, Walter E. Pae, Jr., R. Koerfer, A. El-Banayosy, R. Hetzer, M. Vigano, A. 
Pavie, Penn State Milton S. Hershey Medical Center, Hershey, PA, Bad Oeynhausen 
Heart Center, Bad Oeynhausen, Germany
We recorded neurological events in patients with end-stage heart failure not eligible for
transplant undergoing left ventricular assist device (LVAD) placement with the totally
implantable pulsatile LionHeart LVAS as alterntive to medical therapy (AMT).
Twenty-three patients underwent implantation of the LVAS in a non-randomized, observa-
tional study. Neurologic events were pre-specified as a class of adverse events, reported
by sites, and adjudicated independently. The events were further sub-classified as stroke
(CVA), transient ischemic attack (TIA), intracranial bleed (ICB), or other (e.g., brain
abscess), and whether they were either permanent/disabling or transient/reversible.
there were 24 neurologic events in 13 patients (56.5%). Nine patients experienced either
ICB or CVA, five of which also had a TIA. There were a total of 12 TIAs occuring in eight
patients, five of who also had either an ICB or CVA. Three patients were reported to have
an "other" neurologic event. A total of 11 patients had either a CVA or a TIA as a primary
event, producing an event rate of 0.69 events per pateint-year of follow-up. Placed in
terms of functional outcomes, 8 of the LVAD patients had a permanent/disabling neuro-
logical injury and 7 had a transient/reversible episode. Importantly, at least 1/3 of events
(8/24) occuring in four patients were preventable with improved patient selection and
management.
Neurologic events constitute a significant portion of adverse outcomes in this population
of AMT following LVAD placement. TIA is the most common neurologic event, with 12
events occuring in eight patients. The incidence is similar to that of the REMATCH LVAD
group where 52.9% of patients had neurological dysfunction and 21% were reported to
have experienced either an ICB or at least one TIA. Improvements in device design and
patient selection as well as management will be needed to reduce the risk of neurologic
events in patients supported with LVADs as AMT.
1050-124 Left Ventricular Ejecting Force of the Intra-Aortic 
Balloon Pump Assisted and Nonassisted Beats
Ashraf W. Khir, Michael Y. Henein, Derek G. Gibson, John R. Pepper, Royal Brompton 
Hospital, London, United Kingdom, Brunel University, Uxbridge, United Kingdom
Background: The benefits of the Intra Aortic Balloon Pump (IABP) have been widely
demonstrated, but the underlying mechanisms of these benefits are not fully described.
The left ventricle (LV) ejects the stroke volume with a force that is equal to blood mass
multiplied by its acceleration.
Methods: Aortic root, LV early diastolic filling (E-wave) and left anterior descending coro-
nary (LAD) flow velocities were recorded in 20 patients requiring IABP in the intensive
care unit using transesophageal Doppler echocardiography. Recordings were made at
pumping rates 1:2 and 1:3, leaving a minimum of 15 minutes between recordings to allow
for the return to control state. Flow acceleration at the aortic root was calculated as the
slope of the early part of the velocity curve and velocity time integral (VTI) was calculated
to indicate stroke volume. Diastolic VTI of LAD and LV E-wave velocity curves were also
calculated to indicate LAD and LV filling flow.
Results: LAD peak diastolic flow velocity and its VTI increased significantly at IABP 1:2
by (22±2%), (79±15%), and 1:3 by (17±2%), (67±10%) respectively, compared to non
assisted beats. LV E-wave peak velocity and its VTI increased significantly at IABP 1:2 by
(20±5%), (75±6%), and 1:3 by (11±4%), (60±4%) respectively, compared to non assisted
beats. Although a change in flow acceleration at the aortic root was not observed
between the assisted and non assisted beats, peak velocity and VTI increased signifi-
cantly at IABP 1:2 by (25±4%), (35±5%) and 1:3 by (20±3%), (25±4%) respectively, com-
pared to non assisted beats. The increase in LAD diastolic VTI correlated with the
increase in diastolic E-wave VTI (r = 0.82), which correlated with the increase in aortic
root systolic VTI (r=0.87).
Conclusion: The increase in LAD diastolic flow due to balloon inflation results in an
increase in LV filling flow. The increase in LV filling augments the stroke volume ejected
into the aorta, which is in agreement with Starling law. The increase in the stroke volume
despite the unchanged aortic flow acceleration suggests an increase in the LV ejecting
force of the assisted beats, elucidating one of the benefit of IABP.
1050-125 Clinical Application of a Wear-Resistant Axial Flow 
Pump With an Intelligent Control Algorithm as a Left 
Ventricular Cardiac Assist Device
Johannes Mueller, Yu-Guo Weng, Torsten Drews, Dagmar Kemper, Evgeni Potapov, 
Michael Jurmann, Roland Hetzer, Deutsches Herzentrum Berlin, Berlin, Germany
Background: Since the early application of assist devices it has been a goal to have a
totally wear-resistant system. INCOR, an axial flow pump for left heart support, has a vir-
tually unlimited life due to magnetic suspension of the rotating impeller. Patients with
axial flow pumps show a reduced pulsatility of the blood flow. In order to avoid significant
arrhythmia due to sucking in of myocardial tissue INCOR is implemented with an anti-
suction control algorithm.
Methods: Out of 72 patients supported with the device since June 2002, 31 (1f, 30m;
mean age 53, range 36–65 years) with end-stage heart failure received the system in this
institute. Anticoagulation consisted of heparin postoperatively and of Aspirin, clopidogrel,
and Warfarin later on. For dosage adjustment, INR, thrombelastography and platelet
aggregometry were performed. Furthermore, anti-heart-failure medication was adminis-
tered.
Results: Mean follow-up is 127 (range, 12-454) days; 19 patients are still being sup-
ported. Two patients could be weaned because of cardiac improvement after 178 and
206 days. Two were transplanted and eight died due to multi-organ failure after a mean of
49 (range 22 – 126) days. Three patients showed signs of a transitory ischemic attack
and two had cerebral bleeding. Due to the implemented anti-suction algorithm suction did
not occur in any patient. After 2 months, blood chemistry showed normal values for all
organ functions, in particular no hemolysis (LDH, LDH1 normal) and no deviation of any
blood cell count. None of the patients showed signs of infection (CRP normal). Auto-anti-
bodies against cardiac structures like the beta-1-adrenoceptor disappeared within six
weeks after the implantation.
Conclusions: Application of up-to-date technology in the design of axial flow pumps sig-
nificantly improves the clinical outcome. Especially the problems resulting from chronic
systemic infection and elevated inflammatory status, known as a major problem of car-
diac assist device therapy, seem to be solved. The disappearance of the antibodies after
only six weeks is a sign of a fast immunological recovery. No side effects due to reduced
pulsatility of the blood could be observed.
1050-126 Left Ventricular Assist Device Implantation in Patients 
With Viral Myocarditis-Induced Heart Failure
Nicholas C. Dang, Ranjit John, Jeffrey A. Morgan, Brian J. Lee, Mehmet C. Oz, Yoshifumi 
Naka, Columbia-Presbyterian Medical Center, New York, NY
Background: Viral myocarditis (VM) is a disease entity that exhibits a broad range of
clinical pathways to the onset of cardiac symptoms, but the progression to severe con-
gestive heart failure, both chronic and acute, carries significant morbidity and mortality.
Left ventricular assist device (LVAD) implantation has gained acceptance as a modality
Implantation 30 days 
Post-
Implantation
60 days 
Post-
Implantation
90 days 
Post-
Implantation
Explantation
 Echocardiographic 
Analysis:
LVEF (%) 19.3±6.62 43.5±8.51*** 40.7±10.9*** 36.0±12.7*** -
LVEDD (mmHg) 6.94±1.40 3.31±0.97*** 4.42±1.00*** 4.90±1.40** -
LV mass (gm) - 193±102 192±90.1 220±90.1 -
 Tissue Analysis:
Myocyte Area (µm2) 562±122 - - - 290±63.3***
Myocyte Diameter (µm) 16.9±2.49 - - - 13.0±1.87***
% Collagen Deposition 35.7±7.14 - - - 27.1±4.27***
 Serological 
Analysis:
BNP levels (pg/mL) 225±148 63.8±42.7* - - 16.3±7.71**
 Electrophysiologic 
Analysis:
QTc (msec) 472±56.0 448±48.1 434±34.5* - 461±70.0
QRS (msec) 121±30.4 104±20.3** 104±17.4** - 114±45.4
Notes: Values are the 
means ± SD of the 
listed parameters.
All p-values are 
for t-tests vs 
values at 
implantation.
* p-value < 
0.05.
**p-value < 
0.01.
***p-value < 
0.001.
